Search

Your search keyword '"FAGIUOLI S"' showing total 1,970 results

Search Constraints

Start Over You searched for: Author "FAGIUOLI S" Remove constraint Author: "FAGIUOLI S"
1,970 results on '"FAGIUOLI S"'

Search Results

1. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)

5. T.07.10: BACTERIAL AND FUNGAL INFECTIONS INACLF: PREVALENCE AND IMPACT ON PATIENT MORBIDITY AND MORTALITY

6. OC.11.8: SHORT- AND LONG-TERM RESULTS OF LIVER TRANSPLANTATION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE (ALD) AND ACUTE ON CHRONIC LIVER FAILURE

7. OC.11.4: LIVER TRANSPLANT IN ACLF AND ALD: AN EFFECTIVE OPTION WITH LIMITED ACCESS? PRELIMINARY RESULTS OF A SINGLE CENTER EXPERIENCE

8. Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion

9. A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969–1989 birth-cohort

10. Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients

11. Systemic treatment for hepatocellular carcinoma beyond milan criteria on the waitlist: is it time for a neoadjuvant therapy?

12. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

13. The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients

14. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

15. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

16. One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity

17. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool

18. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)

19. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy

21. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

22. Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome

23. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

24. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

25. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

26. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

27. Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study

28. Meet–Test–Treat for HCV management: patients’ and clinicians’ preferences in hospital and drug addiction services in Italy

29. Liver transplantation in patients with non-neoplastic portal vein thrombosis: 20 years of experience in a single center

30. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

33. Serum procalcitonin predicts mortality independently of the presence of ACLF in patients with cirrhosis and ascites hospitalized for suspicious infection and treated with empiric antibiotic therapy

37. Individualized HBIG withdrawal in an historical cohort of liver transplant recipients in Italy

38. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

40. Current Endovascular Management of Arterial Complications After Pediatric Liver Transplantation in a Tertiary Center

41. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

42. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

43. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

44. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study

45. Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome

46. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

47. Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients

48. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

49. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

50. Drug–drug interactions in italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: Insights from a real-world study

Catalog

Books, media, physical & digital resources